Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biotechnology company whose drug development pipeline relies on animal testing. The company’s research into compounds like zunsemetinib (ATI-450) for inflammatory conditions involves preclinical studies conducted on animals, a practice central to its regulatory submission process for new pharmaceuticals. This places its operations within the commercial exploitation of animals for product development.

The company’s animal testing activities are documented in its published research, including a 2021 study on MK2 inhibition that details the use of animal models. As a pharmaceutical developer, Aclaris is subject to regulatory requirements that mandate animal data, making animal testing an inherent and material component of its business model. There is no public commitment from the company to adopt or fund the development of alternative, non-animal testing methods.